Aims: Hyponatraemia (HN) is the most common electrolyte balance disorder in clinical practice. Since the 1970s, demeclocycline has been used in some countries to treat chronic HN secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). The precise mechanism of action of demeclocycline is unclear, but has been linked to the induction of nephrogenic diabetes insipidus. Furthermore, the safety profile of demeclocycline is variable with an inconsistent time to onset, and a potential for complications. There has been no systematic evaluation of the use of demeclocycline for the treatment of HN secondary to SIADH to date. A systematic literature review was performed to obtain an insight into the clinical safety and efficacy of demeclocycline for this condition. Methods: Embase TM , MEDLINE â , MEDLINE â In-Process, and The Cochrane Library were searched on two occasions using MeSH terms combined with free-text terms. References were screened by two independent reviewers. Relevant publications were then extracted by two independent reviewers, with a third reviewer collating and finalising extractions. Results: The searches returned a total of 705 hits. 632 abstracts were screened after the removal of duplicates. Following screening, 35 full-length publications were reviewed. Of these, 17 were excluded, resulting in 18 studies deemed relevant for data extraction. Two were randomised controlled trials (RCTs), 16 were non-RCTs, and 10 were case reports. Discussion: Although most reports suggest that demeclocycline can address serum sodium levels in specific patients with HN, efficacy is variable, and may depend upon the underlying aetiology. Demeclocycline dose adjustments can be complex, and as its use in clinical practice is not well defined, it can differ between healthcare professionals. Conclusion: There is a lack of clinical and economic evidence supporting the use of demeclocycline for HN secondary to SIADH. Patients receiving demeclocycline for HN secondary to SIADH must be closely monitored.
Introduction
Hyponatraemia (HN), defined as a serum sodium concentration < 135 mmol/l, is the most common metabolic disorder of body water and total body sodium concentration. HN is usually associated with a disturbance in vasopressin [antidiuretic hormone (ADH)], which can be synthesised independently of serum osmolality or circulating fluid volume under specific pathological or pharmacological conditions (1) . Clinical criteria for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) were established by Bartter and Schwartz (2) and have remained largely unchanged ever since (1) . SIADH accounts for one-third of all cases of HN (3) .
Hyponatraemia occurs in approximately 30% of hospitalised patients (1, 4) and is a clinical feature in 15-20% of emergency admissions (1) . HN has a wide range of aetiologies across several patient populations. In the great majority of patients, its aetiology is multifactorial (5) . HN secondary to SIADH is associated with significant morbidity (6) , mortality (7-10) and increased length of hospital stay (11). Symptoms are associated primarily with the severity of the HN, and range from confusion and vomiting in mild HN (< 135 mmol/l sodium) to seizures, coma and death in severe cases (< 125 mmol/l sodium; Figure 1 ) (4, 12, 13) . In addition to symptoms, patients are subject to serious sequelae of HN, including gait abnormalities, falls (14) , and an increased fracture risk (15) . Such morbidities are clinically significant, as HN is particularly common in elderly people (12) .
There is a substantial economic healthcare burden associated with HN, which include significant increases in length of hospital stay, hospital costs and intensive care unit (ICU) costs, as well as an increase in the risk of ICU admission and 30-day hospital readmission. Studies in the USA estimate that direct costs for treating HN range from $1.6 to $3.6 billion annually (16) .
Current management strategies for acute symptomatic HN secondary to SIADH comprise hypertonic (3%) saline given either via bolus or continuous intravenous infusion, with or without diuretics. Patients with euvolaemic hypo-osmolality because of SIADH do not respond to isotonic saline, and occasionally, this causes HN to worsen (16) . In chronic HN (< 135 mmol/l for > 48 h) secondary to SIADH, fluid restriction is considered first-line treatment in patients without severe symptoms or where hypovolaemia is not suspected (1, 16) . Fluid restriction between 500 and 1000 ml/day is recommended, according to HN severity (17) . Pharmacological therapy generally comprises a vaptan (specific vasopressin-2 receptor antagonists) or demeclocycline in some countries (e.g. France and the UK); other options may include urea or loop diuretics or combinations of above treatments (16) .
The aim of HN management was to normalise the serum sodium concentration whilst avoiding the risk of osmotic demyelination syndrome (ODS; previously known as central pontine myelinolysis). It is important to limit the correction of sodium to a maximum rate of 12 mmol/24 h, and to this end, it is important that patients are in an environment suitable for monitoring with regular estimations of sodium levels. If HN is known to be of short duration (< 48 h), correction may be carried out at a faster rate as the risk of cerebral oedema in a patient with severely symptomatic HN outweigh the risks of ODS. It should also be remembered that often, the aim was to restore the sodium to a 'safe' level rather than achieve sodium normalisation. Most physicians suggest regular review of sodium levels and less invasive action once sodium levels reach 120-125 mmol/l (16) .
Demeclocycline is a tetracycline derivative antibiotic, with a marketing authorisation in the UK for the treatment of chronic HN associated with SIADH secondary to malignant disease, where water restriction is ineffective and the patient does not have concomitant cirrhosis (18) . In France, demeclocycline is reimbursed for the treatment of SIADH, particularly with an origin of paraneoplastic syndrome with chronic hyponatraemia (< 125 mmol/l) associated with inappropriate natriuresis, and/or clinical signs associated with hyponatraemia resistant to fluid restriction (19) . Although its mode of action has not yet been established, it is thought that demeclocycline induces nephrogenic diabetes insipidus in approximately 60% of patients with HN secondary to SIADH, resulting in decreased urine concentration and rebalancing of body sodium concentrations (12, 16) . Onset of action is unpredictable, usually occurring after 2-5 days, but occasionally taking longer (3, 12, 16) .
Treatment with demeclocycline has been associated with gastrointestinal intolerance, including nausea and vomiting, nephrotoxicity and renal failure (18) ; cases of reversible renal failure have also been reported (20) (21) (22) . As with all antibiotics, overgrowth of resistant organisms may cause candidiasis (18) .
To our knowledge, there has been no systematic evaluation of the use of demeclocycline for the treatment of HN secondary to SIADH to date, and its use appears to be supported by subjective familiarity rather than objective evidence. Therefore, a systematic literature review of all available evidence was performed to obtain an insight into the clinical safety and efficacy of demeclocycline for this condition. To further understand the financial impact of treating with demeclocycline, an economic component was included within the search criteria.
Methods
A comprehensive search strategy was employed following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) standards (23 Inclusion criteria for the search output were limited to any study examining the clinical efficacy or long-term/real-world effectiveness of demeclocycline, case reports with more than five patients where only clinical efficacy (rather than safety) was reported, or case reports with one or more patients reporting any safety outcomes. In addition, studies presenting costeffectiveness or health-related quality of life (HRQoL) data for demeclocycline in the treatment of HN associated with SIADH were also included.
Potentially relevant references identified from the search output were screened electronically by two independent reviewers and any differences subsequently adjudicated by a third reviewer. Full publications of the resulting, potentially relevant studies were then reviewed before the included study list was finalised. Relevant publications were extracted into a predesigned data extraction table by two independent reviewers, with a third reviewer collating and finalising the extractions. Papers published in languages other than English or French were included only if sufficient data were available in English-language abstracts. Quality assessment was conducted for randomised controlled trials (RCTs) and cohort studies using the 2011 Scottish Intercollegiate Guidelines Network checklists (www.sign.ac.uk).
The comprehensive literature search was performed on 28 May 2014. Subsequently, a second search was undertaken to identify relevant studies published between March and December 2014; searches occurred on the 9 December 2014 and were performed to an identical protocol.
Results

Search outputs
Searches outputs from the initial protocol (28 May 2014) returned 679 hits. After the electronic removal of 71 duplicate references, 608 abstracts were screened. Upon completion of dual electronic screening, the full-length publications of 25 studies were ordered for full review; five further studies were available as conference abstracts only. Of these, 12 were excluded (Appendix B summarises the excluded papers), resulting in 18 studies deemed relevant for data extraction.
Results from the second, updated literature search (March to December 2014) produced 26 hits. After the removal of two duplicate references, 24 abstracts were screened; five studies were identified for full review following electronic screening. Of these, all abstracts were excluded (Appendix B), resulting in no additional studies deemed relevant for data extraction (Figure 2 ).
Systematic review
Of the 18 studies deemed relevant for data extraction, two RCTs were identified ( (25) .
In total, 16 non-RCTs were considered relevant, comprising six cohort studies (four observational studies (20, 22, 26, 27) , two retrospective chart analyses (21, 28) , and 10 case reports (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (Tables 2 and 3 , respectively); no cost-effectiveness or HRQoL studies were identified. Quality assessments for all studies other than case reports are presented (Appendix C).
RCT evidence for the effectiveness and safety of demeclocycline A comparison of demeclocycline with placebo in nine patients with chronic psychiatric illness suggested, there are no significant differences in mean serum sodium concentration after 3 weeks' treatment (131.4 mmol/l and 134.1 mmol/l, respectively). There were no significant differences between treatments in the frequency of episodes of serum sodium levels < 125 mmol/l (p = 0.78). All patients experienced episodes of HN during the study; no adverse events related to demeclocycline were reported (24) .
Horattas et al. reported a prospective, doubleblind, placebo-controlled study of 30 patients undergoing elective CABG. Patients were randomised to receive either placebo or demeclocycline 1200 mg/ day at pre-operative Day 5 and continuing through to postoperative Day 2. Following placebo, serum sodium concentration was significantly reduced from pre-operative levels while serum sodium and osmolality was within normal range in the demeclocycline group (p < 0. reduced level compared with baseline, but not with demeclocycline (25) . Two patients discontinued demeclocycline owing to skin hypersensitivity and gastrointestinal upset, and four reported mild gastrointestinal upset (25) . RCT data for the effectiveness and safety of demeclocycline are presented in Table 4 .
Non-randomised cohort studies of demeclocycline
Four observational cohort studies were identified and reported a total of 39 patients with HN secondary to SIADH. All four studies reported an increase in mean serum sodium levels during treatment with demeclocycline at doses of up to 1200 mg/day (20, 22, 26, 27) . Two studies reported adverse events associated with demeclocycline, including azotemia (nine patients in total; two discontinued demeclocycline), renal function impairment (two patients) and nausea (one patient) (20, 22) . Demeclocycline effectiveness and safety data reported in observational cohort studies are presented in Table 5 . Two retrospective chart analyses reported the impact of demeclocycline in a further 21 patients (21,28).
Brewerton et al. reported on six psychiatric patients with a history of carbamazepine responsiveness who developed clinically significant carbamazepineinduced HN. Treatment with demeclocycline was associated with significant increases in serum sodium levels in five patients compared with pretreatment concentrations (increases from 130.1 to 136.7 mmol/l). Safety data were not reported in this study (28) .
A retrospective review of 15 patients with malignancies treated with demeclocycline for serious HN, without a specific diagnosis of SIADH, reported an increase in mean serum sodium. From pretreatment values of 119 mmol/l, sodium levels were raised to a mean peak of 139 mmol/l after 3-28 days (21) .
In total, 80% of patients (n = 12) developed azotemia and three died within 10 days of receiving demeclocycline. Although the deaths were because of advanced infections and malignancy, three presented with marked azotemia; the renal dysfunction associated with demeclocycline was considered as a possible contributor to the deaths. Of the six patients with severe azotemia (serum urea nitrogen > 25 mg/dl), five patients were receiving concomitant nephrotoxic or antianabolic agents: aminoglycoside antibiotics, amphotericin B and corticosteroid (21) .
Case reports involving demeclocycline
Ten case reports, detailing 11 patients in total, presented safety data pertaining to demeclocycline (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . Demeclocycline effectiveness and safety data reported in case studies are presented in Table 6 .
Three reports associated deterioration in renal function with demeclocycline in four patients with a diagnosis of SIADH (30, 31, 35) . Distinct but reversible episodes of glomerular filtration rate (GFR) reduction were observed in two patients (31) , with acute renal failure reported in a third receiving demeclocycline at up to 2400 mg/day (35) . A fourth patient (94-year-old male hospitalised following collapse and subsequent diagnosis of SIADH) died of irreversible acute renal failure that authors attributed to dehydration associated with demeclocycline 1200 mg/day and a compromised fluid intake (30).
Two case reports described the development of hyperphosphaturia during demeclocycline treatment for HN secondary to SIADH. Upon follow-up, both patients presented with malignancies considered related to elevated phosphate levels, which recovered following discontinuation of demeclocycline. Authors of both reports considered the phosphate diabetes related to selective demeclocycline-induced renal toxicity (29, 32) .
A further two reports describe severe gastric intolerance leading to discontinuation of demeclocycline (33, 34) . In one case, a 76-year-old male admitted with grand mal seizures and a previous history of peptic ulcer, severe gastric intolerance occurred after a single dose of demeclocycline (33) .
A single case study of a 61-year-old male with SIADH reported normalisation of serum sodium levels with demeclocycline (600 mg/day). After a month, demeclocycline was discontinued but followed by a rapid fall in both osmolality and level of consciousness. Reinstitution of treatment led to biochemical and clinical improvement; the patient was discharged on demeclocycline 3 months after admission (36) .
A Japanese report of a 63-year-old female with SIADH treated by strict water restriction, and administration of sodium, dexamethasone and demeclocycline, highlights correction of serum sodium from 93 to 137 mmol/l within 3 days of treatment. Subsequently, the patient became comatose and developed quadriplegia. After 12 months of hospitalisation, the patient died of septic shock. Computed tomography scans and brain stem auditory responses were indicative of ODS (38) . Data for this case study were obtained from the English language abstract and figures presented within the report. A final study reported seizures and altered mental state in a 78-year-old female patient with a history of hypothyroidism, rheumatoid arthritis and early Alzheimer's disease admitted for severe HN, which was considered secondary to SIADH. The patient was treated with demeclocycline (900 mg/day) and discharged under fluid restriction. After 6 weeks, she was readmitted; laboratory investigation identified severe hypernatraemia (serum sodium, 185 mmol/l) resulting from over-correction of HN. The authors recommended that demeclocycline should be reserved for patients for whom strict fluid restriction is unsuitable (39) .
Discussion
Hyponatraemia can lead to a wide spectrum of clinical symptoms and presents in a range of conditions. Despite this, the diagnosis and management of patients remains problematic (1, 3) , particularly because of the heterogeneous nature of HN (40) . In addition, treatment guidance has been generally oversimplistic, without clear consensus, and not reflective of the range of clinical issues encountered in current daily practice (1) .
The literature search and review demonstrates a paucity of available high-quality data for the effectiveness and safety of demeclocycline in the treatment of HN secondary to SIADH; no relevant economic evaluations or HRQoL studies were identified. With the exception of case reports, no published studies have addressed the use of demeclocycline for SIADHassociated HN for more than 15 years (20, 22, (24) (25) (26) (27) . Despite its long history in the treatment of HN secondary to SIADH, the use of demeclocycline is largely based on clinical experience rather than objective evidence. Although a lack of robust evidence from RCTs is by no means uncommon in medicine, a systematic appraisal of all published studies and case reports was necessary to appraise the efficacy and safety of demeclocycline treatment. Examining the studies that are available, only two compared demeclocycline with placebo (24, 25) . Of these RCTs, one did not demonstrate any significant differences in mean serum sodium levels after 3-weeks' treatment. However, this study enrolled patients with psychosis and episodic or chronic polydipsia-associated HN (mean duration of 5.4 years) who did not have a specific diagnosis of SIADH (24) . In addition, the dosing ranges of demeclocycline were initially relatively low (escalating from 600 mg/day to 1200 mg/day by week 3), compared with the recommended initial dose of 900-1200 mg/ day (18) . The second RCT identified also included patients without a diagnosis of SIADH, but concluded that demeclocycline prevented HN because of increased secretion of ADH, commonly seen in patients undergoing CABG procedures (25) .
The mode of action of demeclocycline on ADHinduced water flow is not well understood, but the mechanism of therapeutic effect involves induction of nephrogenic diabetes insipidus (12, 41) . While no studies have systematically evaluated the side effects associated with demeclocycline, several studies have identified safety issues associated with the onset of nephrogenic diabetes insipidus, particularly renal dysfunction (20) (21) (22) 30, 31, 35) . In some patients, polyuria can be profound and patients can become markedly symptomatic, occasionally developing hypernatraemia if access to water is severely restricted (12, 39) . Patients with known liver disease should not receive more than 1 g/day demeclocycline (18) . In addition, monitoring of both renal and hepatic function should be performed regularly (18, 42) .
Onset of action for demeclocycline is unpredictable and reported to range from 2 to 5 days, complicating dose adjustments (12, 16) . Two reports describe severe gastric intolerance leading to treatment discontinuation (33, 34) ; one incident occurred following a single dose of demeclocycline in a 76-year-old male with grand mal seizures and SIADH. Authors suggested a 1200 mg/day dose may have been too high for the second patient: a 75-year-old woman with decline in general condition and pleural effusion who developed vomiting and diarrhoea on Day 4 of treatment (33) . Overall, most reports suggest that demeclocycline is able to increase serum sodium levels in the majority (60%) of patients with HN secondary to SIADH (12) ; treatment effectiveness in patients without a specific SIADH diagnosis may be limited (24) . The safety profile of demeclocycline appears variable with the potential for complications, such as severe hypernatraemia (39) and renal dysfunction (18) . Recent European clinical practice guidelines for diagnosis and treatment of HN recommend against the use of demeclocycline (1) . Thus, close monitoring may be warranted in patients receiving demeclocycline for HN secondary to SIADH.
Conclusions
The results from this systematic literature review highlight the paucity of clinical evidence and lack of economic evidence supporting the use of demeclocycline for HN secondary to SIADH. There is a clinical need to treat HN and manage patients with SIADH appropriately (3); in particular, the management of patients with cancer. For example, chemotherapy may need to be delayed until the normalisation of these patients' sodium levels (43) , and delays to chemotherapy negatively influence outcomes (44) . In addition, some chemotherapy regimens require aggressive hydration strategies (42, 45) . Furthermore, patients may also require hospital admission for the symptomatic consequences of HN, adding to the burden of their cancer (42, 46, 47) .
Although most reports suggest that demeclocycline can address serum sodium levels in HN (12) , efficacy in patients without SIADH may be limited (24) . Moreover, with a variable and unreliable time to onset of action, and a safety profile associated with induction of nephrogenic diabetes insipidus, demeclocycline dose adjustments can be complex (12, 16) . Thus, it may be concluded that patients receiving demeclocycline for HN secondary to SIADH must be closely monitored. (24) Internal validity Does the study address an appropriate and clearly focused question? Yes Quote: 'we undertook a double-blind, placebo-controlled study of demeclocycline in psychiatric patients with polydipsia-hyponatraemia' Is the assignment of subjects to treatment groups randomised? Yes Order of treatment was randomly assigned; study used a cross-over method Is an adequate concealment method used? Unclear Study was double-blind and placebo-controlled, but details on method of concealment were unclear Are subjects and investigators kept 'blind' about treatment allocation? Unclear Study was double-blind and placebo-controlled, but details on method of blinding were unclear
